Upfront combination therapy with metformin and the DPP-4* inhibitor vildagliptin may improve glycaemic durability in patients newly diagnosed with type 2 diabetes (T2D) compared with sequential therapy with metformin monotherapy followed by vildagliptin, results from the VERIFY** trial showed.
The novel dual GIP* and GLP-1** receptor agonist tirzepatide demonstrated clinically meaningful improvements in glycaemic control and weight loss in patients with type 2 diabetes (T2D), according to data presented at EASD 2019.
The addition of the dual SGLT*1 and SGLT2 inhibitor sotagliflozin to insulin led to improvements in glycaemic control, body weight, and systolic blood pressure (SBP) in overweight/obese individuals with type 1 diabetes (T1D), according to a post hoc analysis presented at EASD 2019.
In patients with type 2 diabetes (T2D) inadequately controlled on metformin, semaglutide may have a greater impact than canagliflozin in reducing HbA1c levels and bodyweight, according to the phase IIIb SUSTAIN 8* trial presented at EASD 2019.
The incidence of cardiovascular (CV) death, nonfatal myocardial infarction (MI), or nonfatal stroke (three-point MACE*) was comparable in individuals with early stage type 2 diabetes (T2D) who received the DPP-4** inhibitor linagliptin or the sulfonylurea glimepiride in addition to usual care, according to results of the CAROLINA*** trial.
Women who conceive singleton pregnancies following assisted reproductive technology (ART) may have a higher risk of developing gestational diabetes than those who conceive spontaneously, according to results of a systematic review and meta-analysis presented at EASD 2019.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacist - Malaysia digital copy today!
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Pharmaceutical industry representatives highlighted lesser-known career opportunities for licensed pharmacists at the recent Pharmaceutical Industries Pharmacists Insights 3.0 (PIPI 3.0) symposium in Petaling Jaya.